Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
British Journal of Clinical Pharmacology|February 21, 2016
Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibodyGerald R Galluppi, Nicolas Wisniacki, Chris Stebbins
Journal of Clinical Pharmacology|April 17, 2014
Interferon beta assessment in non-Chinese and Chinese subjects: pharmacokinetics and pharmacodynamic activity of an endogenous cytokine are not race dependentMark C Rogge, Yun Liu, Gerald R Galluppi
Combinatorial Chemistry & High Throughput Screening|January 8, 2010
Plasma protein binding in drug discovery and developmentMonique L Howard, John J Hill, Gerald R Galluppi, et al.
Pharmacology Research & Perspectives|March 25, 2024
Evaluation of OCT2-mediated drug-drug interactions between ulotaront and metformin in subjects with schizophreniaGuangqing Xiao, Hironobu Tsukada, Yu-Luan Chen, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 16, 2003
Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam)Melissa V Langston, Mysore P Ramprasad, Tugrul T Kararli, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 26, 2021
A sensitive LC-MS/MS method for simultaneous quantification of ulotaront and its N-desmethyl metabolite in human plasma and application to a clinical studyYu-Luan Chen, Yao Shi, Amber LaFayette, et al.
Pharmaceutical Research|April 28, 2022
In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT<sub>1A</sub> Receptor Agonist for the Treatment of SchizophreniaGuangqing Xiao, Yu-Luan Chen, Nina Dedic, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 22, 2021
Population pharmacokinetic analysis of ulotaront in subjects with schizophreniaGerald R Galluppi, Daniel G Polhamus, Jeannine M Fisher, et al.
Clinical Therapeutics|August 10, 2013
Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritisNicolas Wisniacki, Lakshmi Amaravadi, Gerald R Galluppi, et al.
Drug Metabolism and Bioanalysis Letters|January 7, 2026
A Physiologically-Based Pharmacokinetic Model to Characterize Dasotraline Pharmacokinetics and CYP-mediated Drug-Drug InteractionsGuangqing Xiao, Jing Lin, Yu-Luan Chen, et al.
Pageof 2